Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/ refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study

Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Prajwal C. Boddu, Mansour Alfayez, Jorge E. Cortes, Marina Konopleva, Farhad Ravandi-Kashani, Elias Jabbour, Tapan Kadia, Graciela M. Nogueras-Gonzalez, Jing Ning, Naveen Pemmaraju, Courtney D. Dinardo, Michael Andreeff, Sherry A. Pierce, Tauna Gordon, Steven M. Kornblau, Wilmer Flores, Zainab AlhamalCarlos Bueso-Ramos, Jeffrey L. Jorgensen, Keyur P. Patel, Jorge Blando, James P. Allison, Padmanee Sharma, Hagop Kantarjian

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Fingerprint Dive into the research topics of 'Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/ refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences